Quinazoline Sulfonamides as Dual Binders of the Proteins B-Cell Lymphoma 2 and B-Cell Lymphoma Extra Long with Potent Proapoptotic Cell-Based Activity
- Author(s)
- Sleebs, BE; Czabotar, PE; Fairbrother, WJ; Fairlie, WD; Flygare, JA; Huang, DCS; Kersten, WJA; Koehler, MFT; Lessene, G; Lowes, K; Parisot, JP; Smith, BJ; Smith, ML; Souers, AJ; Street, IP; Yang, H; Baell, JB;
- Details
- Publication Year 2011-03-24,Volume 54,Issue #6,Page 1914-1926
- Journal Title
- JOURNAL OF MEDICINAL CHEMISTRY
- Publication Type
- Journal Article
- Abstract
- ABT-737 and ABT-263 are potent inhibitors of the BH3 antiapoptotic proteins, Bcl-x(L) and Bcl-2. This class of putative anticancer agents invariantly contains an acylsulfonamide core. We have designed and synthesized a series of novel quinazoline-based inhibitors of Bcl-2 and Bcl-xL that contain a heterocyclic alternative to the acylsulfonamide. These compounds exhibit submicromolar, mechanism-based activity in human small-cell lung carcinoma cell lines in the presence of 10% human serum. This comprises the first successful demonstration of a quinazoline sulfonamide core serving as an effective benzoylsulfonamide bioisostere. Additionally, these novel quinazolines comprise only the second known class of Bcl-2 family protein inhibitors to induce mechanism-based cell death.
- Publisher
- AMER CHEMICAL SOC
- Research Division(s)
- Chemical Biology; Structural Biology; Molecular Genetics Of Cancer
- Publisher's Version
- https://doi.org/10.1021/jm101596e
- NHMRC Grants
- NHMRC/461221, NHMRC/575561,
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2011-03-24 12:00:00
Last Modified: 2015-03-24 10:01:03